FDA Approves Lisraya as Oral Treatment for Dermatomyositis
WASHINGTON, D.C. — The Food and Drug Administration approved Priovant Therapeutics Inc.’s Lisraya for adults with dermatomyositis, providing an oral treatment for the rare autoimmune disease after a Phase 3 …
FDA Approves Lisraya as Oral Treatment for Dermatomyositis Read More